



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Impact of taxane-based chemotherapeutics on male reproductive function

Citation for published version:

Kanodia, C, Rimmer, MP, Duffin, K & Mitchell, RT 2023, 'Impact of taxane-based chemotherapeutics on male reproductive function', *Reproduction & Fertility*, vol. 4, no. 1, e220134. <https://doi.org/10.1530/RAF-22-0134>

Digital Object Identifier (DOI):

[10.1530/RAF-22-0134](https://doi.org/10.1530/RAF-22-0134)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Reproduction & Fertility

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Impact of taxane-based chemotherapeutics on male reproductive function

Journal:	<i>Reproduction and Fertility</i>
Manuscript ID	RAF-22-0134.R1
Manuscript Type:	Research Letter
Date Submitted by the Author:	n/a
Complete List of Authors:	Kanodia , Charvi ; The University of Edinburgh, Edinburgh Medical School Rimmer, Michael; The University of Edinburgh, MRC Centre for Reproductive Health Duffin, Kathleen; The University of Edinburgh, 3. Biomedical Sciences Mitchell, Rod; Centre for Reproductive Health
Keywords:	Fertility preservation, Fertility

SCHOLARONE™
Manuscripts

Impact of taxane-based chemotherapeutics on male reproductive function

Charvi Kanodia ^{1*}, Michael P Rimmer ^{2*} Kathleen Duffin ^{3*}, Rod T Mitchell ²

1. Edinburgh Medical School, University of Edinburgh, UK.

2. MRC Centre for Reproductive Health, University of Edinburgh, UK.

3. Biomedical Sciences, University of Edinburgh, UK.

* All authors have contributed equally to this work

Charvi Kanodia ORCID: 0000-0002-2187-516X

Michael P Rimmer ORCID: 000-0002-3295-8753

Kathleen Duffin ORCID: 0000-0003-0039-8525

Rod T Mitchell ORCID: 0000-0003-4650-3765

Correspondence: Rod.Mitchell@ed.ac.uk

Lay Summary

20 Men and boys with cancer treated with chemotherapy are known to have reduced
21 fertility following their treatment. This is because some chemotherapy drugs can
22 damage the cells in the testicles that make sperm. This study found there is limited
23 information available on the effect of one group of chemotherapy drugs, called
24 taxanes, on testicular function and fertility. More studies are needed to aid clinicians
25 in advising patients on how this taxane-based chemotherapy may affect their future
26 fertility.

28 Letter

29 Chemotherapy exposure may reduce fertility in males. Adult men may cryopreserve
30 sperm prior to commencing cancer therapy; however, for pre-pubertal males who do
31 not produce sperm, fertility preservation remains experimental. At present, no human
32 has ever been born from cryopreserved pre-pubertal testis tissue, with the most
33 recent breakthrough in this area being the birth of a Rhesus Macaque following
34 autologous transplant of cryopreserved pre-pubertal testis tissue (Fayomi et al.,
35 2019). Current clinical practice on male pre-pubertal fertility preservation, varies
36 globally in terms of eligibility for tissue cryopreservation, methods and duration of
37 storage, future clinical use and consensus on assessment of tissue function and
38 reproductive outcomes.

39 Although numerous chemotherapeutics are used to treat cancers, the impact of
40 different agents on reproductive function and fertility is poorly understood. Taxane-

41 based chemotherapeutics are used to treat numerous cancers; however, robust data
42 on their impact on male fertility is lacking. We reviewed the literature on effects of
43 taxane-based chemotherapy in male patients on subsequent gonadal function and
44 fertility.

45 We systematically searched PubMed and Scopus using previously published
46 methodology (Tian En et al., 2020) and registered our protocol (PROSPERO-
47 CRD42021296306) the search terms used in this review are outlined in

48 Supplementary Table 1. We included studies reporting effects of taxane-based
49 chemotherapy on testicular development and function using PRISMA guidelines.

50 We identified 458 studies, of which 87 were assessed for eligibility (Supplementary
51 Table 2). Five studies met inclusion criteria (Figure 1) and involved 512 patients, with
52 94 eligible for this review (male patients receiving taxanes) the characteristics of
53 these studies can be found in Table 1.

54 All five studies reported testosterone levels, 3/5 reported gonadotrophin levels, and
55 1/5 reported fatherhood, sperm count/analysis, inhibin B and testicular volume.

56 Two studies (Pectasides et al., 2009, Chatzidarellis et al., 2010) specifically reported
57 reproductive outcomes in patients who received taxane chemotherapy with all
58 patients (n=70) in these studies receiving paclitaxel and additional chemotherapy,
59 and neither study included a control group.

60 Chatzidarellis et al reported 40 male patients (aged 28 and 60 yrs) receiving
61 paclitaxel or docetaxel; identifying a significant reduction in inhibin B, an increase in

62 FSH, and a decrease in bilateral testicular volume, with no significant change in LH
63 (Chatzidarellis *et al.*, 2010). Whilst information about total taxane dose per patient is
64 provided, outcome measures are not reported for individual patients.

65 Pectasides *et al* report on 30 male patients (aged 17-62 yrs) treated with paclitaxel,
66 methotrexate, ifosfamide and cisplatin for poor-risk non-seminoma germ cell
67 tumours; outcome measures were available for 21 patients. Serum FSH levels were
68 significantly elevated 12 months after treatment completion; however, they returned
69 to normal levels at 18 months post-treatment. LH and testosterone levels were
70 unaffected. Overall, 17/21 (80.9%) patients demonstrated recovery of
71 spermatogenesis post-treatment, and a total of five patients had gone on to father
72 children.

73 For the remaining three studies, 24/442 patients received taxane chemotherapy.
74 However, no studies report outcomes of individual patients or stratified by treatment
75 received (Strasser *et al.*, 2006, Burney *et al.*, 2012, Rothermundt *et al.*, 2018).

76 Limited data are available on taxane-based chemotherapy and reproductive
77 outcomes, with no data available for prepubertal males. The single study reporting
78 on spermatogenesis showed that sperm production resumed in the majority of
79 patients (Pectasides *et al.*, 2009), while studies reporting endocrine function post-
80 taxane treatment demonstrated elevated FSH (Chatzidarellis *et al.*, 2010, Pectasides
81 *et al.*, 2009) and reduced inhibin-B (Chatzidarellis *et al.*, 2010). The impact of
82 specific dosing regimens or duration of treatment on reproductive outcomes could

83 not be determined. Prospective data collection on endocrine function, semen
84 analysis and fatherhood for males receiving taxane-based chemotherapy is required
85 in order to inform clinicians when counselling patients receiving these
86 chemotherapeutics on their future fertility. Given the experimental nature of fertility
87 preservation for pre-pubertal male the importance of understanding of how taxane-
88 based chemotherapy can impact future fertility cannot be understated.

89

90

91 **Declaration of interest**

92 The authors declare that there is no conflict of interest that could be perceived as
93 prejudicing the impartiality of this review.

94 **Funding**

95 M P R and R T M are funded by a MRC Centre for Reproductive Health Grant No:
96 MR/N022556/1.

97 R T M is funded by a UK Research and Innovation (UKRI) Future Leaders
98 Fellowship MR/S017151/1.

99

100 **Author contribution statement**

101 CK, MPR and RTM conceived the idea for the article. MPR and KD undertook the
102 literature search. MPR, CK and KD screened abstracts, extracted data and wrote the

103 manuscript. MPR produced tables and figures. CK, MPR, KD and RTM wrote the
104 article and approved it for submission.

105

106 **References**

107 BURNEY, B. O., CARDWELL, G., PAPUSHA, V., HAYES, T. G., KONDA, B.,
108 AUCHUS, R. J., SMIECHOWSKA, J., GARCIA, J. M. & BHARGAVA, P. 2012. Low
109 testosterone levels and increased inflammatory markers in patients with cancer and
110 relationship with cachexia. *Journal of Clinical Endocrinology and Metabolism*, 97,
111 E700-E709.

112

113 CHATZIDARELLIS, E., MAKRILIA, N., GIZA, L., GEORGIADIS, E., ALAMARA, C. &
114 SYRIGOS, K. N. 2010. Effects of taxane-based chemotherapy on inhibin B and
115 gonadotropins as biomarkers of spermatogenesis. *Fertil Steril*, 94, 558-63.

116

117 FAYOMI, A. P., PETERS, K., SUKHWANI, M., VALLI-PULASKI, H., SHETTY, G.,
118 MEISTRICH, M. L., HOUSER, L., ROBERTSON, N., ROBERTS, V., RAMSEY, C.,
119 HANNA, C., HENNEBOLD, J. D., DOBRINSKI, I. & ORWIG, K. E. 2019. Autologous
120 grafting of cryopreserved prepubertal rhesus testis produces sperm and offspring.
121 *Science*, 363, 1314-1319.

122

123 PECTASIDES, D., PECTASIDES, E., PAPAXOINIS, G., SKONDRA, M.,
124 GEROSTATHOU, M., KARAGEORGOPOULOU, S., KAMPOSIORAS, C.,

- 125 TOUNTAS, N., KOUMARIANOU, A., PSYRRI, A., MACHERAS, A. &
126 ECONOMOPOULOS, T. 2009. Testicular function in poor-risk nonseminomatous
127 germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin
128 combination chemotherapy. *J Androl*, 30, 280-6.
- 129
130 ROTHERMUNDT, C., THURNEYSEN, C., CATHOMAS, R., MÜLLER, B.,
131 MINGRONE, W., HIRSCHI-BLICKENSTORFER, A., WEHRHAHN, T., RUF, C.,
132 ROTHSCHILD, S., SEIFERT, B., TERBUCH, A., GRASSMUGG, T., WOELKY, R.,
133 FANKHAUSER, C., KUNIT, T., FISCHER, N., INAUEN, R., KAMRADT, J., ZIEGLER,
134 K., HAYNES, A., JÜNI, P. & GILLESSEN, S. 2018. Baseline characteristics and
135 patterns of care in testicular cancer patients: first data from the Swiss Austrian
136 German Testicular Cancer Cohort Study (SAG TCCS). *Swiss Med Wkly*, 148,
137 w14640.
- 138
139 STRASSER, F., PALMER, J. L., DEGRACIA, B., WILLEY, J. S., SCHOVER, L. R.,
140 YUSUF, S. W., PISTERS, K., VASSILOPOULOU-SELLIN, R. & BRUERA, E. 2006.
141 The impact of hypogonadism and autonomic dysfunction on fatigue, emotional
142 function, and sexual desire in male with advanced cancer: A pilot study. *Cancer*, 107,
143 2949-2957.
- 144
145 TIAN EN, L., BROUGHAM, M. F. H., WALLACE, W. H. B. & MITCHELL, R. T. 2020.
146 Impacts of platinum-based chemotherapy on subsequent testicular function and
147 fertility in boys with cancer. *Human Reproduction Update*, 26, 874-885.

148

Impact of taxane-based chemotherapeutics on male reproductive function

Charvi Kanodia ^{1*}, Michael P Rimmer ^{2*} Kathleen Duffin ^{3*}, Rod T Mitchell ²

1. Edinburgh Medical School, University of Edinburgh, UK.

2. MRC Centre for Reproductive Health, University of Edinburgh, UK.

3. Biomedical Sciences, University of Edinburgh, UK.

* All authors have contributed equally to this work

Charvi Kanodia ORCID: 0000-0002-2187-516X

Michael P Rimmer ORCID: 000-0002-3295-8753

Kathleen Duffin ORCID: 0000-0003-0039-8525

Rod T Mitchell ORCID: 0000-0003-4650-3765

Correspondence: Rod.Mitchell@ed.ac.uk

Lay Summary

20 Men and boys with cancer treated with chemotherapy are known to have reduced
21 fertility following their treatment. This is because some chemotherapy drugs can
22 damage the cells in the testicles that make sperm. This study found there is limited
23 information available on the effect of one group of chemotherapy drugs, called
24 taxanes, on testicular function and fertility. More studies are needed to aid clinicians
25 in advising patients on how this taxane-based chemotherapy may affect their future
26 fertility.

28 Letter

29 Chemotherapy exposure may reduce fertility in males. Adult men may cryopreserve
30 sperm prior to commencing cancer therapy; however, for pre-pubertal males who do
31 not produce sperm, fertility preservation remains experimental. **At present, no human
32 has ever been born from cryopreserved pre-pubertal testis tissue, with the most
33 recent breakthrough in this area being the birth of a Rhesus Macaque following
34 autologous transplant of cryopreserved pre-pubertal testis tissue (Fayomi et al.,
35 2019). Current clinical practice on male pre-pubertal fertility preservation, varies
36 globally in terms of eligibility for tissue cryopreservation, methods and duration of
37 storage, future clinical use and consensus on assessment of tissue function and
38 reproductive outcomes.**

39 Although numerous chemotherapeutics are used to treat cancers, the impact of
40 different agents on reproductive function and fertility is poorly understood. Taxane-

41 based chemotherapeutics are used to treat numerous cancers; however, robust data
42 on their impact on male fertility is lacking. We reviewed the literature on effects of
43 taxane-based chemotherapy in male patients on subsequent gonadal function and
44 fertility.

45 We systematically searched PubMed and Scopus using previously published
46 methodology (Tian En et al., 2020) and registered our protocol (PROSPERO-
47 CRD42021296306) **the search terms used in this review are outlined in**
48 **Supplementary Table 1.** We included studies reporting effects of taxane-based
49 chemotherapy on testicular development and function using PRISMA guidelines.
50 We identified 458 studies, of which 87 were assessed for eligibility (Supplementary
51 Table 2). Five studies met inclusion criteria (Figure 1) and involved 512 patients, with
52 94 eligible for this review (male patients receiving taxanes) **the characteristics of**
53 **these studies can be found in Table 1.**

54 All five studies reported testosterone levels, 3/5 reported gonadotrophin levels, and
55 1/5 reported fatherhood, sperm count/analysis, inhibin B and testicular volume.

56 Two studies (Pectasides et al., 2009, Chatzidarellis et al., 2010) specifically reported
57 reproductive outcomes in patients who received taxane chemotherapy with all
58 patients (n=70) in these studies receiving paclitaxel and additional chemotherapy,
59 and neither study included a control group.

60 Chatzidarellis et al reported 40 male patients (aged 28 and 60 yrs) receiving
61 paclitaxel or docetaxel; identifying a significant reduction in inhibin B, an increase in

62 FSH, and a decrease in bilateral testicular volume, with no significant change in LH
63 (Chatzidarellis *et al.*, 2010). Whilst information about total taxane dose per patient is
64 provided, outcome measures are not reported for individual patients.

65 Pectasides et al report on 30 male patients (aged 17-62 yrs) treated with paclitaxel,
66 methotrexate, ifosfamide and cisplatin for poor-risk non-seminoma germ cell
67 tumours; outcome measures were available for 21 patients. Serum FSH levels were
68 significantly elevated 12 months after treatment completion; however, they returned
69 to normal levels at 18 months post-treatment. LH and testosterone levels were
70 unaffected. Overall, 17/21 (80.9%) patients demonstrated recovery of
71 spermatogenesis post-treatment, and a total of five patients had gone on to father
72 children.

73 For the remaining three studies, 24/442 patients received taxane chemotherapy.
74 However, no studies report outcomes of individual patients or stratified by treatment
75 received (Strasser et al., 2006, Burney et al., 2012, Rothermundt et al., 2018).

76 Limited data are available on taxane-based chemotherapy and reproductive
77 outcomes, with no data available for prepubertal males. The single study reporting
78 on spermatogenesis showed that sperm production resumed in the majority of
79 patients (Pectasides et al., 2009), while studies reporting endocrine function post-
80 taxane treatment demonstrated elevated FSH (Chatzidarellis et al., 2010, Pectasides
81 et al., 2009) and reduced inhibin-B (Chatzidarellis et al., 2010). The impact of
82 specific dosing regimens or duration of treatment on reproductive outcomes could

83 not be determined. Prospective data collection on endocrine function, semen
84 analysis and fatherhood for males receiving taxane-based chemotherapy is required
85 in order to inform clinicians when counselling patients receiving these
86 chemotherapeutics on their future fertility. Given the experimental nature of fertility
87 preservation for pre-pubertal male the importance of understanding of how taxane-
88 based chemotherapy can impact future fertility cannot be understated.

89

90

91 **Declaration of interest**

92 The authors declare that there is no conflict of interest that could be perceived as
93 prejudicing the impartiality of this review.

94 **Funding**

95 M P R and R T M are funded by a MRC Centre for Reproductive Health Grant No:
96 MR/N022556/1.

97 R T M is funded by a UK Research and Innovation (UKRI) Future Leaders
98 Fellowship MR/S017151/1.

99

100 **Author contribution statement**

101 CK, MPR and RTM conceived the idea for the article. MPR and KD undertook the
102 literature search. MPR, CK and KD screened abstracts, extracted data and wrote the

103 manuscript. MPR produced tables and figures. CK, MPR, KD and RTM wrote the
104 article and approved it for submission.

105

106 **References**

107 BURNEY, B. O., CARDWELL, G., PAPUSHA, V., HAYES, T. G., KONDA, B.,
108 AUCHUS, R. J., SMIECHOWSKA, J., GARCIA, J. M. & BHARGAVA, P. 2012. Low
109 testosterone levels and increased inflammatory markers in patients with cancer and
110 relationship with cachexia. *Journal of Clinical Endocrinology and Metabolism*, 97,
111 E700-E709.

112

113 CHATZIDARELLIS, E., MAKRILIA, N., GIZA, L., GEORGIADIS, E., ALAMARA, C. &
114 SYRIGOS, K. N. 2010. Effects of taxane-based chemotherapy on inhibin B and
115 gonadotropins as biomarkers of spermatogenesis. *Fertil Steril*, 94, 558-63.

116

117 FAYOMI, A. P., PETERS, K., SUKHWANI, M., VALLI-PULASKI, H., SHETTY, G.,
118 MEISTRICH, M. L., HOUSER, L., ROBERTSON, N., ROBERTS, V., RAMSEY, C.,
119 HANNA, C., HENNEBOLD, J. D., DOBRINSKI, I. & ORWIG, K. E. 2019. Autologous
120 grafting of cryopreserved prepubertal rhesus testis produces sperm and offspring.
121 *Science*, 363, 1314-1319.

122

123 PECTASIDES, D., PECTASIDES, E., PAPAXOINIS, G., SKONDRA, M.,
124 GEROSTATHOU, M., KARAGEORGOPOULOU, S., KAMPOSIORAS, C.,

125 TOUNTAS, N., KOUMARIANOU, A., PSYRRI, A., MACHERAS, A. &
126 ECONOMOPOULOS, T. 2009. Testicular function in poor-risk nonseminomatous
127 germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin
128 combination chemotherapy. *J Androl*, 30, 280-6.

129
130 ROTHERMUNDT, C., THURNEYSEN, C., CATHOMAS, R., MÜLLER, B.,
131 MINGRONE, W., HIRSCHI-BLICKENSTORFER, A., WEHRHAHN, T., RUF, C.,
132 ROTHSCHILD, S., SEIFERT, B., TERBUCH, A., GRASSMUGG, T., WOELKY, R.,
133 FANKHAUSER, C., KUNIT, T., FISCHER, N., INAUEN, R., KAMRADT, J., ZIEGLER,
134 K., HAYNES, A., JÜNI, P. & GILLESSEN, S. 2018. Baseline characteristics and
135 patterns of care in testicular cancer patients: first data from the Swiss Austrian
136 German Testicular Cancer Cohort Study (SAG TCCS). *Swiss Med Wkly*, 148,
137 w14640.

138
139 STRASSER, F., PALMER, J. L., DEGRACIA, B., WILLEY, J. S., SCHOVER, L. R.,
140 YUSUF, S. W., PISTERS, K., VASSILOPOULOU-SELLIN, R. & BRUERA, E. 2006.
141 The impact of hypogonadism and autonomic dysfunction on fatigue, emotional
142 function, and sexual desire in male with advanced cancer: A pilot study. *Cancer*, 107,
143 2949-2957.

144
145 TIAN EN, L., BROUGHAM, M. F. H., WALLACE, W. H. B. & MITCHELL, R. T. 2020.
146 Impacts of platinum-based chemotherapy on subsequent testicular function and
147 fertility in boys with cancer. *Human Reproduction Update*, 26, 874-885.

148


Figure 1 – PRISMA flow diagram

Table 1: Studies which met inclusion criteria. *Outcome measures are only listed if relevant to this review. **Patients were eligible if they were male, treated with taxane chemotherapy, and had one or more reproductive outcome reported.

Authors	Study design	Study aim	Outcome measures*	Pre-pubertal patients included	Total patients	Eligible patients**	Summary of results	Commentary
Pectasides 2009	Controlled clinical study	To investigate the effect of methotrexate, paclitaxel, ifosfamide, and cisplatin on fertility in poor-risk nonseminomatous germ cell tumors	Testosterone, FSH, LH, sperm analysis, fatherhood	No	30	30	The majority of men demonstrated recovery of spermatogenesis. Leydig cell function was not affected.	All patients received paclitaxel
Chatzidarellis 2010	Controlled clinical study	To assess the effects of taxanes on the male reproductive axis	FSH, LH, inhibin B, testicular volume	No	40	40	Following taxane chemotherapy there was a significant reduction in inhibin B, increase in FSH, and decrease in bilateral testicular volume, with no significant change in LH.	All patients received paclitaxel
Strasser 2006	Cross-sectional study	To assess whether hypogonadism and autonomic dysfunction contribute to fatigue, decreased sexual desire, and depression in patients with incurable cancer	Testosterone, FSH, LH	No	48	23	64% had hypogonadism and this was associated with fatigue and negative mood.	23 patients had paclitaxel; results were not stratified by treatment
Burney 2012	Cross-sectional study	To determine the relationship between testosterone levels, inflammation, and symptom burden in male cancer patients	Testosterone	No	95	12	Testosterone levels were lower in patients with cancer cachexia than non-cachexia and non-cancer controls	12 patients received taxane chemotherapy; results were not stratified by treatment.
Rothermundt 2018	Cohort study	To present baseline characteristics and treatment strategies for patients with primary or relapsed germ cell tumours	Testosterone	No	299	1	7.3% of seminoma and 5.6% of non-seminoma patients had low testosterone levels	One patient received paclitaxel; results were not stratified by treatment.

Supplementary Table 1 – Search terms and strategy for identification of publications relating to fertility outcomes after taxane-based chemotherapy in childhood cancer survivors. Search strategy adapted from Tian 2020.

Taxanes and Germ Cell - PubMed	
Male	((male[tiab] OR males OR boy OR boys OR boyfriend OR boyhood OR man OR men))
Taxanes	AND (((((((((((paclitaxel) OR docetaxel) OR taxus) OR taxol) OR taxotere) OR taxane) OR cabazitaxel) OR Jevtana) OR kabazitaxel) OR 33069-62-4) OR 114977-28-5) OR 183133-96-2)
Childhood cancer	AND (((((((((((((((((((((((((((((((((((leukemia) OR leukaemia) OR leukemic*) OR leukaemic*) OR leukaemi*) OR childhood ALL) OR AML) OR lymphoma) OR lymphom*) OR Hodgkin) OR hodgkin*) OR T-cell) OR B-cell) OR non-hodgkin) OR sarcoma) OR sarcom*) OR sarcoma) OR Ewing's) OR Ewing*) OR osteosarcoma) OR osteosarcom*) OR wilms tumor) OR wilms*) OR nephroblastom*) OR neuroblastoma) OR neuroblastom*) OR rhabdomyosarcoma) OR rhabdomyosarcoma*) OR teratoma) OR teratom*) OR hepatoma) OR hepatom*) OR hepatoblastoma) OR hepatoblastom*) OR PNET) OR Medulloblastoma) OR medulloblastom*) OR PNET*) OR Neuroectodermal tumors, primitive) OR Retinoblastoma) OR retinoblastom*) OR meningioma) OR meningiom*) OR glioma) OR gliom*) OR pediatric oncology) OR paediatric oncology) OR childhood cancer) OR childhood tumor) OR childhood tumors) OR brain tumor*) OR brain tumour*) OR brain neoplasms) OR central nervous system neoplasm) OR central nervous system neoplasms) OR central nervous system tumor*) OR central nervous system tumour*) OR brain cancer*) OR brain neoplasm*) OR intracranial neoplasm*) OR testis neoplasm) OR neoplasm, testicular) OR testicular neoplasm) OR testicular neoplasms) OR testis cancer) OR testicular cancer) OR testis tumor) OR testicular cancer) OR cancer of testis) OR testis neoplasm*) OR testis tumour*) OR testis tumor*) OR leukemia, lymphocytic, acute)
Germ cell	AND (((((((((((((((((((((((((((((((((((Spermatogenesis) OR gonadal disorder) OR spermiogenesis) OR spermatocytogenesis) OR spermatogenic failure) OR azoospermia) OR oligospermia) OR asthenozoospermia) OR teratozoospermia) OR oligoasthenoteratozoospermia) OR dysspermia) OR normozoospermic) OR semen) OR semen analysis) OR semen quality) OR sperm) OR sperm count) OR sperm motility) OR spermatozoa) OR progeny) OR offspring) OR posterity) OR fertility) OR infertility) OR subfertility) OR reproduction) OR fertilization) OR conception) OR paternity) OR fatherhood) OR parenthood) OR pregnancy outcome) OR fertile) OR infertile) OR subfertile) OR sperm maturation) OR aspermia) OR spermatozoon abnormality) OR germ cell) OR spermatogonia) OR spermatogonial) OR spermatogonium) OR meiosis) OR gonocyte) OR spermatid) OR spermatids) OR follicle stimulating hormone) OR FSH)

Taxanes and Germ Cell – Embase	
Male	((male.ti,ab,kw. OR males OR boy OR boys OR boyfriend OR boyhood OR man OR men))
Ifosfamide/ cyclophosphamide	AND (((((((((((paclitaxel) OR docetaxel) OR taxus) OR taxol) OR taxotere) OR taxane) OR cabazitaxel) OR Jevtana) OR kabazitaxel) OR 33069-62-4) OR 114977-28-5) OR 183133-96-2)
Childhood cancer	AND (((((((((((((((((((((((((((((((((((leukemia) OR leukaemia) OR leukemic*) OR leukaemic*) OR leukaemi*) OR childhood ALL) OR AML) OR lymphoma) OR lymphom*) OR Hodgkin) OR hodgkin*) OR T-cell) OR B-cell) OR non-hodgkin) OR sarcoma) OR sarcom*) OR sarcoma) OR Ewing's) OR Ewing*) OR osteosarcoma) OR osteosarcom*) OR wilms tumor) OR wilms*) OR nephroblastom*) OR neuroblastoma) OR neuroblastom*) OR rhabdomyosarcoma) OR rhabdomyosarcoma*) OR teratoma) OR teratom*) OR hepatoma) OR hepatom*) OR hepatoblastoma) OR hepatoblastom*) OR PNET) OR Medulloblastoma) OR medulloblastom*) OR PNET*) OR Neuroectodermal tumors, primitive) OR Retinoblastoma) OR retinoblastom*) OR meningioma) OR meningiom*) OR glioma) OR gliom*) OR pediatric oncology) OR paediatric oncology) OR childhood cancer) OR childhood tumor) OR childhood tumors) OR brain tumor*) OR brain tumour*) OR brain neoplasms) OR central nervous system neoplasm) OR central nervous system neoplasms) OR central nervous system tumor*) OR central nervous system tumour*) OR brain cancer*) OR brain neoplasm*) OR intracranial neoplasm*) OR testis neoplasm) OR neoplasm, testicular) OR testicular neoplasm) OR testicular neoplasms) OR testis cancer) OR testicular cancer) OR

	testis tumor) OR testicular cancer) OR cancer of testis) OR testis neoplasm*) OR testis tumour*) OR testis tumor*) OR leukemia, lymphocytic, acute)
Sertoli cell	AND (((((((Sertoli) OR anti-mullerian) OR AMH) OR inhibin) OR inhibin B) OR androgen receptor))

Taxanes and Leydig Cell - PubMed	
Male	((male[tiab] OR males OR boy OR boys OR boyfriend OR boyhood OR man OR men))
Taxanes	AND (((((((((((paclitaxel) OR docetaxel) OR taxus) OR taxol) OR taxotere) OR taxane) OR cabazitaxel) OR Jevtana) OR kabazitaxel) OR 33069-62-4) OR 114977-28-5) OR 183133-96-2)
Childhood cancer	AND (((((((((((((((((((((((((((((((((((leukemia) OR leukaemia) OR leukemic*) OR leukaemic*) OR leukaemi*) OR childhood ALL) OR AML) OR lymphoma) OR lymphom*) OR Hodgkin) OR hodgkin*) OR T-cell) OR B-cell) OR non-hodgkin) OR sarcoma) OR sarcom*) OR sarcoma) OR Ewing's) OR Ewing*) OR osteosarcoma) OR osteosarcom*) OR wilms tumor) OR wilms*) OR nephroblastom*) OR neuroblastoma) OR neuroblastom*) OR rhabdomyosarcoma) OR rhabdomyosarcoma*) OR teratoma) OR teratom*) OR hepatoma) OR hepatom*) OR hepatoblastoma) OR hepatoblastom*) OR PNET) OR Medulloblastoma) OR medulloblastom*) OR PNET*) OR Neuroectodermal tumors, primitive) OR Retinoblastoma) OR retinoblastom*) OR meningioma) OR meningiom*) OR glioma) OR gliom*) OR pediatric oncology) OR paediatric oncology) OR childhood cancer) OR childhood tumor) OR childhood tumors) OR brain tumor*) OR brain tumour*) OR brain neoplasms) OR central nervous system neoplasm) OR central nervous system neoplasms) OR central nervous system tumor*) OR central nervous system tumour*) OR brain cancer*) OR brain neoplasm*) OR intracranial neoplasm*) OR testis neoplasm) OR neoplasm, testicular) OR testicular neoplasm) OR testicular neoplasms) OR testis cancer) OR testicular cancer) OR testis tumor) OR testicular cancer) OR cancer of testis) OR testis neoplasm*) OR testis tumour*) OR testis tumor*) OR leukemia, lymphocytic, acute)
Leydig cell	AND (((((((((((((((((((((((((((((((((((androgen hormone insufficiency) OR leydig cell) OR leydig failure) OR testicular failure) OR interstitial cell failure) OR gonadal failure) OR hypogonadism) OR low testosterone) OR testosterone deficiency) OR leydig cell insufficiency) OR androgen deficiency) OR low testosterone*) OR hypogonadism*) OR leydig cell*) OR testosterone) OR luteinising hormone) OR LH) OR steroidogenesis) OR puberty) OR pubertal) OR testicular volume) OR testis volume) OR tanner stage) OR tanner staging) OR androgen) OR androgens) OR androgenic))

Taxanes and Leydig Cell - Embase	
Male	((male.ti,ab,kw. OR males OR boy OR boys OR boyfriend OR boyhood OR man OR men))
Taxanes	AND (((((((((((((((paclitaxel) OR docetaxel) OR taxus) OR taxol) OR taxotere) OR taxane) OR cabazitaxel) OR Jevtana) OR kabazitaxel) OR 33069-62-4) OR 114977-28-5) OR 183133-96-2)
Childhood cancer	AND (((((((((((((((((((((((((((((((((((leukemia) OR leukaemia) OR leukemic*) OR leukaemic*) OR leukaemi*) OR childhood ALL) OR AML) OR lymphoma) OR lymphom*) OR Hodgkin) OR hodgkin*) OR T-cell) OR B-cell) OR non-hodgkin) OR sarcoma) OR sarcom*) OR sarcoma) OR Ewing's) OR Ewing*) OR osteosarcoma) OR osteosarcom*) OR wilms tumor) OR wilms*) OR nephroblastom*) OR neuroblastoma) OR neuroblastom*) OR rhabdomyosarcoma) OR rhabdomyosarcoma*) OR teratoma) OR teratom*) OR hepatoma) OR hepatom*) OR hepatoblastoma) OR hepatoblastom*) OR PNET) OR Medulloblastoma) OR medulloblastom*) OR PNET*) OR Neuroectodermal tumors, primitive) OR Retinoblastoma) OR retinoblastom*) OR meningioma) OR meningiom*) OR glioma) OR gliom*) OR pediatric oncology) OR paediatric oncology) OR childhood cancer) OR childhood tumor) OR childhood tumors) OR brain tumor*) OR brain tumour*) OR brain neoplasms) OR central nervous system neoplasm) OR central nervous system neoplasms) OR central nervous system tumor*) OR central nervous system tumour*) OR brain cancer*) OR brain neoplasm*) OR intracranial neoplasm*) OR testis neoplasm) OR neoplasm, testicular) OR testicular neoplasm) OR testicular neoplasms) OR testis cancer) OR testicular cancer) OR testis tumor) OR testicular cancer) OR cancer of testis) OR testis neoplasm*) OR testis tumour*) OR testis tumor*) OR leukemia, lymphocytic, acute)
Leydig cell	AND (((((((((((((((((((((((((((((((((((androgen hormone insufficiency) OR leydig cell) OR leydig failure) OR testicular failure) OR interstitial cell failure) OR gonadal failure) OR hypogonadism) OR low testosterone) OR testosterone deficiency) OR leydig cell insufficiency) OR androgen deficiency) OR low testosterone*) OR hypogonadism*) OR leydig cell*) OR testosterone) OR luteinising hormone) OR LH) OR steroidogenesis) OR puberty) OR pubertal) OR testicular volume) OR testis volume) OR tanner stage) OR tanner staging) OR androgen) OR androgens) OR androgenic))

	luteinising hormone) OR LH) OR steroidogenesis) OR puberty) OR pubertal) OR testicular volume) OR testis volume) OR tanner stage) OR tanner staging) OR androgen) OR androgens) OR androgenic))
--	---

For Review Only

Supplementary Table 1: Full text articles screened and excluded

Study	Title	Journal	Volume	Issue	Pages
Chovanec 2014	Adenocarcinoma of the rete testis - a rare case of testicular malignancy	Clin Oncol	27	2	136-7
Gerl 1996	Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor	Anti-Cancer Drugs	7	6	716-8
Hamid 2019	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era	Clin Genitourin Cancer	17	1	58-64.e1
Pamenter 2003	Bilateral testicular cancer: A preventable problem? Experience from a large cancer centre	BJU International	92	1	43-46
Sottotetti 2015	A case of metastatic adenocarcinoma of submandibular gland with hyperexpression of androgen and HER2 receptor: A "target driven" therapeutic strategy	Italian Journal of Medicine	9	SUPPL . 2	101-102
Nitta 2016	A Case of Mixed Germ Cell Tumor in the Intramedullary Spinal-cord	Tokai J Exp Clin Med	41	3	147-51
Lin 2021	Cervical malignant teratoma masquerading as a hematoma: a case report	Journal of International Medical Research	49	2	
Pont 1997	Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: a retrospective multicenter study of the Austrian Study Group on Urologic Oncology	Ann Oncol	8	12	1229-34
Shiraishi 2018	Chemotherapy for metastatic testicular cancer: The first nationwide multi-institutional study by the Cancer Registration Committee of the Japanese Urological Association	International Journal of Urology	25	8	730-736
Lian 2019	Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy-Refractory Testicular Tumors	Oncologist	24	12	e1437- e1442
Ji 2021	Clinical experience of male primary choriocarcinoma at the samsung medical center	Cancer Research and Treatment	53	3	874-880
Bokemeyer 2008	Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group	Ann Oncol	19	3	448-53

Necchi 2014	Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes	Clin Genitourin Cancer	12	1	63-69.e1
Kondagunta 2005	Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors	J Clin Oncol	23	27	6549-55
Batra 2019	Early experience with chemotherapy intensification for poorprognosis metastatic germ cell cancer and unfavorable tumor marker decline	Canadian Urological Association Journal	14	2	43-47
Seidel 2016	Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group	Urol Oncol	34	4	167.e21-8
Badreldin 2016	The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach	BJU International	117	3	418-23
Shatara 2020	Final report of the prospective NEXT/CNS-GCT-4 consortium trial (gempox followed by marrowablative chemotherapy) in patients with refractory/ recurrent CNS germ cell tumors	Neuro-Oncology	22	SUPPL 3	
Kumano 2007	First-line high-dose chemotherapy combined with peripheral blood stem cell transplantation for patients with advanced extragonadal germ cell tumors	International Journal of Urology	14	4	336-338
Mardiak 2005	Gemcitabine plus cisplatin and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study	Neoplasma	52	3	243-7
Vozianov 2014	High dose chemotherapy in patients with germ cell testicular tumors with unfavorable prognosis	European Urology, Supplements	13	6	e1243
Hara 2005	High dose chemotherapy including paclitaxel (T-ICE) combined with peripheral blood stem cell transplantation for male germ cell tumor. Preliminary report	International Journal of Urology	12	12	1074-8
Lewin 2014	High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients	Intern Med J	44	8	771-8

Stemmer 1996	High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial	J Clin Oncol	14	5	1463-72
Kojima 2015	Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor	International Journal of Urology	22	10	923-7
Nakamura 2015	Importance of continuous sequential chemotherapy and multimodal treatment for advanced testicular cancer: a high-volume Japanese center experience	Medicine (Baltimore)	94	11	e653
Marwaha 2007	The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse	Canadian Journal of Urology	14	5	3692-6
Ronnen 2005	Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy	J Clin Oncol	23	28	6999-7004
Ishioka 2007	Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: a report of three cases	International Journal of Urology	14	5	455-7
Tanaka 2010	Long-term outcome of chemotherapy for advanced testicular and extragonadal germ cell tumors: A single-center 27-year experience	Japanese Journal of Clinical Oncology	40	1	73-78
Nicolai 2009	Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours	BJU International	104	3	340-6
Oechsle 2011	Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors	Eur Urol	60	4	850-5
Mulherin 2015	Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant	Am J Clin Oncol	38	4	373-6
deWit 1999	Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP	International Journal of Cancer	83	6	831-3
Pectasides 2010	Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors	Urol Oncol	28	6	617-23
Motzer 2000	Paclitaxel (Taxol) combination therapy for resistant germ cell tumors	Semin Oncol	27	1 Suppl 1	33-5
Motzer 1997	Paclitaxel in salvage therapy for germ cell tumors	Semin Oncol	24	5 Suppl 15	S15-83-s15-85

Mardiak 2005	Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study	Neoplasma	52	6	497-501
McNeish 2004	Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours	Br J Cancer	90	6	1169-75
Mardiak 2007	Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study	Neoplasma	54	3	240-5
Kawai 2003	Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer	Jpn J Clin Oncol	33	3	127-31
Motzer 2000	Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer	J Clin Oncol	18	12	2413-8
Nonomura 2007	Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors	International Journal of Urology	14	6	527-31
Tryakin 2011	Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study	Urology	78	3	620-5
Eggerer 2007	Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors	Cancer	109	3	528-535
Fizazi 2014	Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial	Lancet Oncol	15	13	1442-1450
Nieto 2005	Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies	Biol Blood Marrow Transplant	11	4	297-306
Chiappori 2008	Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer	Clin Cancer Res	14	5	1464-9
Hartmann 2007	Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group	J Clin Oncol	25	36	5742-7

Feldman 2015	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors	Clin Genitourin Cancer	13	5	453-60
Weiss 2017	A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)	Br J Cancer	117	1	33-40
Theodore 2008	A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors	Ann Oncol	19	8	1465-1469
LigiaCebotaru 2016	A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression	J buon	21	3	698-708
Sadeghi 2013	Phase II study of gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (pts) with refractory germ cell tumor (rGCT): Final results	Journal of Clinical Oncology	31	15 SUPPL . 1	
Beyer 1996	Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer	Annals of Oncology	7	1	31-34
Hinton 2002	Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group	J Clin Oncol	20	7	1859-63
Einhorn 2007	Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant	J Clin Oncol	25	5	513-6
Shamash 2007	A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours	Ann Oncol	18	5	925-30
Sandler 1998	A phase II trial of paclitaxel in refractory germ cell tumors	Cancer	82	7	1381-6
Motzer 1994	Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors	J Clin Oncol	12	11	2277-83
Feldman 2013	Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate-or poor-risk germ cell tumors (GCT)	Journal of Clinical Oncology	31	6 SUPPL . 1	
Mead 2005	A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage	Br J Cancer	93	2	178-84

	chemotherapy for patients with metastatic germ cell cancer: a medical research council trial					
Rosenthal 2009	Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02	International Journal of Radiation Oncology, Biology, Physics	73	3	672-8	
Finlay 2015	Preliminary results of a feasibility pilot study of "gempox" (gemcitabine, oxaliplatin, and paclitaxel) in pediatric and adult patients with refractory or recurrent central nervous system (CNS) germcell tumors (GCT): The international CNS GCT consortium trial, CNS GCT-4	Neuro-Oncology	17	SUPPL . 3		
Bokemeyer 1994	Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer	Journal of Cancer Research & Clinical Oncology	120	12	754-7	
Liu 2013	Preliminary results of a prospective feasibility pilot study of "GEMPOX" (gemcitabine, oxaliplatin, and paclitaxel) in patients with refractory or recurrent CNS germ cell tumours	British Journal of Neurosurgery	27	4	e22-e23	
Narayan 2016	Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors	Clin Genitourin Cancer	14	6	524-529	
Yamada 2013	Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin (DIN) for patients with advanced germ cell tumors: a preliminary report	Jpn J Clin Oncol	43	7	734-9	
Shiraishi 2009	Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors	Int J Clin Oncol	14	5	436-41	
Park 2011	Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors	Onkologie	34	08-Sep	416-20	
DePasquale 2020	Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience	Pediatric Blood and Cancer	67	3	e28125	
Rick 2001	Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and	J Clin Oncol	19	1	81-8	

	thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer					
Sonnichsen 1994	Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors	J Clin Oncol	12	3	532-8	
Seymour 1999	Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy	Leukemia	13	11	1735-40	
Lotz 2005	Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial	Ann Oncol	16	3	411-8	
Passos-Coelho 2011	Suboptimal survival of male germ-cell tumors in southern Portugal-a population-based retrospective study for cases diagnosed in 1999 and 2000	Annals of Oncology	22	5	1215-1220	
Gamulin 2020	Testicular cancer-between de-escalation and high-dose chemotherapy with peripheral blood stem-cell transplantation	Libri Oncologici	48	SUPPL 1	56-57	
Mascia 2015	Testicular cancer: Clinical features in a retrospective survey analysis of a single institution of sardinia	Anticancer Research	35	6	3717-3718	
DeBacker 2006	Testicular germ cell tumors in children: Management and outcome in a series of 20 patients	J Pediatr Urol	2	3	197-201	
Tran 2017	Treatment and outcomes of central nervous system nongerminomatous germ cell tumors with early relapse during induction chemotherapy	Pediatric Neurology	71		106	
Pashankar 2018	Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study	Pediatric Blood and Cancer	65	8	e27111	
DeGiorgi 2004	Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience	Am J Clin Oncol	27	5	457-60	